Comparing Athersys (ATHX) & ObsEva (OBSV)

Athersys (NASDAQ: ATHX) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, profitability and valuation.


This table compares Athersys and ObsEva’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Athersys -746.04% -113.63% -86.25%
ObsEva N/A -74.99% -66.38%

Institutional & Insider Ownership

21.0% of Athersys shares are owned by institutional investors. Comparatively, 35.9% of ObsEva shares are owned by institutional investors. 9.4% of Athersys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Athersys and ObsEva’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Athersys $17.35 million 13.25 -$15.33 million ($0.26) -7.46
ObsEva N/A N/A -$30.20 million ($2.18) -4.49

Athersys has higher revenue and earnings than ObsEva. Athersys is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Athersys and ObsEva, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Athersys 0 0 3 0 3.00
ObsEva 0 0 6 0 3.00

Athersys presently has a consensus price target of $9.50, indicating a potential upside of 389.69%. ObsEva has a consensus price target of $20.33, indicating a potential upside of 107.69%. Given Athersys’ higher possible upside, equities analysts plainly believe Athersys is more favorable than ObsEva.


ObsEva beats Athersys on 6 of the 11 factors compared between the two stocks.

About Athersys

Athersys, Inc. is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients. In the neurological area, the Company evaluated in a completed Phase II trial, the potential for MultiStem treatment of patients with a history of neurological damage from an ischemic stroke. The Company initiated a Phase II clinical study in the United States for the administration of MultiStem cell therapy to patients with a history of an acute myocardial infarction, or AMI.

About ObsEva

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: OBE2109 is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and blocks the endogenous GnRH from activating its pituitary receptors, which reduces estrogen production by the ovaries and leads to amenorrhea. OBE001 (nolasiban) is an oral, new generation oxytocin antagonist with the potential to inhibit uterine contractions at the time of embryo transfer, thereby enhancing embryo implantation during assisted reproductive technologies (ART). BE022 is an orally active small molecule dinoprost (PGF2a) receptor antagonist.

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit